寿胎丸的药物组成及其补肾安胎的药效学研究
|
摘要
目的:
本研究以临床药效确切的补肾安胎复方寿胎丸为研究对象,以肾虚-黄体抑制大鼠流产模型(病-证结合模型)为研究载体,以流产率、雌二醇(E_2)、孕激素(P)、孕激素受体(PR)的表达为评价追踪指标,对寿胎丸进行提取方法的筛选,并通过均匀设计对寿胎丸进行复方组成及配伍规律的研究,经药效验证筛选出补肾安胎的优选配比方,总结并验证了肾虚-黄体抑制大鼠流产造模的标准流程,初步建立了寿胎丸补肾安胎的药效学评价体系。
方法:
实验一:
购置组成复方的各道地药材,并进行生药鉴定。在前期研究基础结合文献研究,确定复方寿胎丸溶液的不同提取方法并制备成为寿胎丸水提液(A药液)、乙醇提取液(B药液)、醇提后药渣水提液(C药液)、醇提+醇提后药渣水提液(B+C药液)。妊娠第1日至第9日以450mg/kg/d羟基脲灌胃,第10天时予以米非司酮(RU486)4.0mg/kg建立肾虚自然流产模型。将70只SPF级SD孕鼠随机分为7个组:①正常对照组;②模型组对照组(羟基脲+米非司酮);③阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组);④寿胎丸A组(羟基脲+米非司酮+寿胎丸水提液);⑤寿胎丸B组(羟基脲+米非司酮+乙醇提液);⑥寿胎丸C组(羟基脲+米非司酮+寿胎丸乙醇提取后药渣水提液);⑦寿胎丸B+C组(羟基脲+米非司酮+寿胎丸乙醇提取液与醇提后药渣水提液的混合液)。
24小时后无菌低温条件下处死大鼠,取子宫经滤纸吸干、称重、计算胚胎数、流产率、测量胚胎直径。用电化学发光法测定血清E_2、P水平。无菌低温条件下取出同侧大鼠子宫新鲜的蜕膜组织,30分钟内采用qRT-PCR方法检测蜕膜组织PR mRNA的表达。
实验二:
通过均匀设计得到8个不同剂量配比的寿胎丸组方,将110只SPF级SD孕鼠随机分为11个组:正常对照组(简称对照组)、模型组对照组(羟基脲+米非司酮)、阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组)、8个不同配比的寿胎丸用药组。造模方法、检测方法同实验一。
分别进行多元回归分析、典型相关分析、直接最优化分析、综合加权分析,并结合均匀设计软件预报设计及临床用药经验,筛选出理论优选方。
实验三:
在实验二得出的理论优选方的基础上,将60只SPF级SD孕鼠随机分为6个组:①模型组对照组(羟基脲+米非司酮);②阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组);③寿胎丸临床常用量组(菟丝子:桑寄生:续断:阿胶=20:10:10:5);④寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0);⑤寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0);⑥寿胎丸优选3号方(菟丝子:桑寄生:续断:阿胶=30:21:21:5)。
造模方法与检测方法同实验一。经统计分析得出剂量配比优选方。
结果:
建立肾虚-黄体抑制大鼠流产模型的标准流程,孕鼠表现出中医肾虚证侯、脏器指数下降,流产率升高,分泌E_2、P水平降低,PRmRNA表达下调。经寿胎丸治疗后能够改善上述流产状态,抑制流产率、增加E_2、P水平,上调PRmRNA表达,来实现保护胚胎的作用。
实验一:
1寿胎丸A组、B组、C组和(B+C)组大鼠的体重、饮食量、卵巢指数、连胎子宫指数与模型组比较,差异无显著性(P＞0.05)。
2在流产率方面,寿胎丸A组、B组、C组和(B+C)组大鼠的流产率与模型组比较,差异有显著性(P＜0.05)。A组、B组、C组、B+C组大鼠的流产率与阳性对照组比较差异无显著性(P＞0.05)。A组、B组、C组、B+C组大鼠的流产率各组间比较,差异无显著性(P＞0.05)。
3在雌激素水平方面,寿胎丸A组、B组、C组和B+C组大鼠的雌二醇水平与模型组比较,差异无显著性(P＞0.05)。
4在孕激素水平方面,寿胎丸A组、B组、C组大鼠的孕激素水平与模型组比较,差异无显著性(P＞0.05)。B+C组大鼠的孕激素水平与模型组比较,差异有显著性(P＜0.05)。A组、B组、C组、B+C组大鼠的孕激素水平与阳性对照组比较,差异无显著性(P＞0.05)。
5在孕激素受体表达方面,寿胎丸A组、C组大鼠的孕激素受体的表达与模型组比较,差异无显著性(P＞0.05)。寿胎丸B组、B+C组大鼠孕激素受体的表达与模型组比较,差异有显著性(P＜0.05)。B组大鼠的孕激素受体的表达与B+C组比较,差异无显著性(P＞0.05)。
6通过等值加权综合计算各指标与模型组的相对百分率,在寿胎丸各个提取方法中,B+C组与模型组的相对百分率最高,推测B+C组防治流产的作用最强。
7综合各指标进行多元方差分析时,4个指标平衡等值加权处理后比较,差异有显著性(P＜0.05),在降低流产率方面,B+C组＞B组＞C组＞A组;在提高E_2水平方面,B+C组＞A组＞C组＞B组;在提高P水平方面,B+C组＞A组＞C组＞B组;在上调PR表达方面,B+C组＞B组＞A组＞C组。综上B+C组防治流产的作用最强。与寿胎丸各提取部位与模型组的相对百分率的推断一致。
实验二、三:
1模型组大鼠的连胎子宫指数与对照组比较,差异有显著性(P＜0.05)。阳性组、组二、组四、组五、组六组大鼠的连胎子宫指数与模型组比较,差异有显著性(P＜0.05)。
2模型组大鼠的流产率与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三、组四、组五、组六、组七和组八大鼠的流产率与模型组比较,差异有显著性(P＜0.01)。
3模型组大鼠血清中雌激素水平与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三的大鼠血清中雌激素水平与模型组比较,差异有显著性(P＜0.05)。
4模型组大鼠血清中孕激素水平与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三、组四、组六大鼠血清中孕激素水平与模型组比较,差异有显著性(P＜0.05)。
5模型组大鼠子宫蜕膜中孕激素受体表达与对照组比较,差异有显著性(P＜0.05)。组一、组二、组三、组四、组五、组六子宫蜕膜中孕激素受体与模型组比较,差异有显著性(P＜0.05)。
6寿胎丸组成药物的关系:
6.1各单味药的补肾安胎贡献度的定性分析:菟丝子＞桑寄生=续断＞阿胶。
6.2交互作用中:菟丝子与桑寄生、菟丝子与阿胶的交互作用与流产率有相关性;菟丝子与桑寄生、桑寄生与续断的交互作用与E_2有相关性;菟丝子与桑寄生、菟丝子与阿胶、桑寄生与续断、桑寄生与阿胶、续断与阿胶的交互作用与P有相关性;菟丝子与桑寄生、菟丝子与阿胶、桑寄生与续断交互作用与PR有相关性。
7将药效学指标与不同剂量配比的寿胎丸相关联,经二次回归得到的回归方程为(R~2=0.9832,P＜0.05):(?)=35.0123-0.2204*X1*X3-0.02321*X1*X4+0.2165X2X3+0.01078*X1~2得到理论优选寿胎丸方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)。
8由验证实验得出,寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)、寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0)、寿胎丸常量方(菟丝子:桑寄生:续断:阿胶=20:10:10:5)与模型组比较,差异有显著性(P＜0.05)。但组间比较,差异无统计学意义(P＞0.05)。
结论:
1罗颂平教授创立的肾虚-黄体抑制(病证结合)流产模型,成功模拟了临床上肾虚型自然流产的状态。本研究在总结前期研究的基础上,初步制定肾虚-黄体抑制(病证结合)流产模型的SOP。
2初步确立了寿胎丸的提取流程,并通过药效学实验筛选得到经醇提+醇提后水提的寿胎丸对肾虚流产大鼠模型的补肾安胎药效最优。
3验证了寿胎丸可明显降低流产率,寿胎丸具有拮抗米非司酮,促进妊娠黄体和合体滋养细胞分泌功能,提高血清E_2、P水平,通过增加孕激素受体mRNA的转录来上调PR的表达,通过改善孕鼠的肾虚状态来实现保护胚胎的作用。
4寿胎丸组成的药物关系:①各单味药的贡献度的定性分析:菟丝子＞桑寄生=续断＞阿胶;②交互作用的定性分析:菟丝子与桑寄生交互作用与各个指标均有相关性;桑寄生与续断的交互作用与E_2、P、PR有相关性;菟丝子与阿胶的交互作用与流产率、P、PR有相关性;续断与阿胶的交互作用与P有相关性。③定性研究初步证明了寿胎丸配伍关系,菟丝子与桑寄生交互作用(君臣关系)＞桑寄生与续断的交互作用(臣佐关系)＞续断与阿胶的交互作用(佐使关系);菟丝子与桑寄生交互作用(君臣关系)＞菟丝子与阿胶的交互作用(君使关系)＞续断与阿胶的交互作用(佐使关系),与原方的配伍关系基本一致。
5验证了阿胶在原方中处于使药的地位,起调和药性的作用,在本实验研究中阿胶的补肾安胎作用不显著。
6将药效学指标与不同剂量配比的寿胎丸相关联,经二次回归得到的回归方程为(R~2=0.9832,P＜0.05):(?)=35.0123-0.2204*X1*X3-0.02321*X1*X4++0.2165X2X3+0.01078*X1~2
经最优分析得出理论优选寿胎丸方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)。
7经过药效验证实验,寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)、寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0)与寿胎丸常量方(菟丝子:桑寄生:续断:阿胶＝20:10:10:5)均具有较好的补肾安胎作用,与阳性对照药物抑制流产作用相当。寿胎丸优选2号方＞阳性对照药物＞寿胎丸优选1号方＞常量方,均可以保护胚胎、降低流产率。
8本研究初步建立了系统的寿胎丸补肾安胎作用的药效学评价体系,规范改良了造模方法、筛选了药效评价的指标,运用数学方法与计算机技术相结合研究复方组方关系和优选配比,并审慎地分析了实验结果,为寿胎丸深层次的配伍规律及药效物质基础研究奠定了基础。
Objective:
Pharmacological experiments,the effect of Shou Tai Wan(STW) on abortion animal models of corepus luteum inhibition due to renal deficiency,were performed in order to bring out the optimal extration method,the optimal proportion and the compatibility rule of STW.
Methods:
Experiment 1:
Collection of Genuine Medicinal Materials and Pharmacognostic identification of Semen Cuscutae,Herba Taxilli,Radix Dipsaci,Colla Corii asini were prepared in accordance with Chinese Pharmacopoeia.SA rats model of corepus luteum inhibition due to renal deficiency was made by intragsstric administration of hydroxycarbamide 450mg/kg/D in dioestrus.Mifepristone(RU 486) was used by intragsstric administration in 10~(th) day.SPF 70 pregnant SD rats,10 weeks old,weight 280～300g were randomly divided into 7 groups:①normal control group;②model group(Hydroxyurea + mifepristone);③positive control group(Hydroxyurea + mifepristone + dydrogeterone);④STW A(aqueous extract solution of STW);⑤STW B(ethanol-extracts of STW);⑥STW C(aqueous extract solution of guffs after alcohol extracting);⑦STW B+C(ethanol-extracts of STW + aqueous extract solution of guffs after alcohol extracting).
Generalized case of rats in every group was observered.Rats were killed after 24 hours,the following data was measured:embryos number,abortion rats sand diameter of embryos.Decidua tissue on one side was collected in 30 minutes after rats death in asepsis condition to detect expression of PR by quantitative RT-PCR.Serum estradiol(E_2),progestogen(P) were measured by chemiluminescence.
Experiment 2:
8 combinations of STW were obtained by uniform design.SPF 110 pregnant SD rats,10 weeks old,weight 280～300g were randomly divided into 11 groups:①normal control group;②model group(Hydroxyurea + mifepristone);③positive control group(Hydroxyurea + mifepristone + dydrogeterone);④8 combinations of STW by uniform design.Animal model building and detection Methods were similar to Experiment 1.
The optimal proportion of STW in theory was obtained by multiple regression analysis,canonical correlation analysis,optimum analysis,integrated weighting analysis.
Experiment 3:
SPF 60 pregnant SD rats,10 weeks old,weight280～300g were randomly divided into 6groups:①model group(Hydroxyurea + mifepristone);②positive control group(Hydroxyurea + mifepristone + dydrogeterone);③clinical routine dose of STW;④STW1(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15: 21:21:0);⑤STW 2(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20: 10:10:0);⑥STW 2(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=30: 21:21:5).Animal model building and detection Methods were similar to Experiment 1.
Results:
Experiment 1:
1.Intake of food/water,changes of pregnant rat body weight in 4~(th) and 9~(th) day,organ index in pregnant rats:compared with model group,there was no significant difference in all groups(P＞0.05).
2.Abortion rate of pregnant rat:compared with model group,there was significant difference on abortion rate between model group and other groups (P＜0.05).Compared with positive control group,there was no significant difference in STW A group,STW B group,STW C group and STW B+C group(P＞0.05).
3.The mean levels of serum E_2:compared with model group,there was no significant difference in STW A group,STW B group,STW C group and STW B+C group(P＞0.05).
4.The mean levels of serum P:compared with model group,there was no significant difference in STW A group,STW B group and STW C group(P＞0.05). The mean levels of serum P in STW B+C group was significantly different from model group(P＜0.05).Compared with positive control group,there was no significant difference in STW A group,STW B group,STW C group,STW B+C group (P＞0.05).
5.Expression of PR:compared with model group,there was no significant difference in STW A group,STW C group(P＞0.05).Expression of PR in STW B group and STW B+C group was significantly different from model group (P＜0.05).There was no significant difference between STW A group and STW C group(P＞0.05).
6.The mean relative percentages compared with model group,which was calculated by Weighted Average Method,indicated that STW B+C group was better than other groups on SA rats model model
7.Multivariate analysis of variance on 4 indexes of pharmacodynamic experiment indicated that STW B+C group＞STW B group＞STW C group＞STW A group in abortion rate of pregnant rat;STW B+C group＞STW A group＞STW C group＞STW B group in the mean levels of serum E_2;STW B+C group＞STW A group＞STW C group＞STW B group in the mean levels of serum P;STW B+C group＞STW B grou＞STW A group＞STW C group in expression of PR.It is suggested STW B+C group was better than other groups on SA rats model model.
Experiment 2:
1.Intake of food/water,changes of pregnant rat body weight in 4~(th) day:compared with model group,there was no significant difference in all groups(P＞0.05).
2.Organ index in pregnant rats:there was significant difference between control group and model group(P＜0.05).Organ index of pregnant rats in positive control group,group2,group4,group5,group6 was significantly different from model group(P＜0.05).
3.Abortion rate of pregnant rat:there was significant difference on abortion rate between control group and model group(P＜0.05).Abortion rate of pregnant rat in positive control group,group1,group2,group4, group5,group6,group7,group8 was significantly different from model group (P＜0.01).
4.The mean levels of serum E_2:there was significant difference on the levels of serum E_2 between control group and model group(P＜0.05). The mean levels of serum E_2 in positive control group,group1,group2,group3 was significantly different from model group(P＜0.05).
5.The mean levels of serum P:there was significant difference on the levels of serum P between control group and model group(P＜0.05). The mean levels of serum P in positive control group,group1,group2, group3,group4,group6 was significantly different from model group(P＜0.05).
6.Expression of PR:there was significant difference on expression of PR between control group and model group(P＜0.05).Expression of PR in group1,group2,group3,group4,group5,group6 was significantly different from model group(P＜0.05).
7.The Compatibility Rule of STW:
7.1 Qualitative Analysis of contribution degrees of single medicine in STW:
Semen Cuscutae＞Herba Taxilli=Radix Dipsaci＞Colla Corii
7.2 Qualitative Analysis of interactions of single medicine in STW:
It is suggested that abortion rate of pregnant rat is associated with interactions between Semen Cuscutae and Herba Taxilli,interactions between Semen Cuscutae and Colla Corii.The mean levels of serum E_2 is related to interactions between Semen Cuscutae and Herba Taxilli,interactions between Herba Taxilli and Radix Dipsaci.The mean levels of serum P is associated with interactions between Semen Cuscutae and Herba Taxilli, interactions between Herba Taxilli and Colla Corii,interactions between Radix Dipsaci and Colla Corii.Expression of PR is associated with 125interactions between Semen Cuscutae and Herba Taxilli,interactions between Semen Cuscutae and Colla Corii,interactions between Herba Taxilli and Radix Dipsaci.
8.Amount of each crude drug in 8 combinations of STW and the mean levels of serum E_2 and P,expression of PR results of 8 combinations of STW on abortion rat models are interrelated by quadratic regression. The equation(R~2=0.9832,P＜0.05) (?)=35.0123-0.2204*X1*X3-0.02321*X1*X4++0.2165X2X3+0.01078*X1~2 was obtained. The optimal proportion of STW are(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15:21:21:0).
9 It was concluded from authentication experiment that compared with model group,there was significant difference in STW 1 group(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15:21:21:0),STW 2 group(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20:10:10:0),STW 3 group (Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20:10:10:5).
Conclusion:
1.Abortion animal models of corepus luteum inhibition due to renal deficiency,which was established by Professor Luo Song Ping,successfully analogue renal deficiency of spontaneous abortion.
本研究以临床药效确切的补肾安胎复方寿胎丸为研究对象,以肾虚-黄体抑制大鼠流产模型(病-证结合模型)为研究载体,以流产率、雌二醇(E_2)、孕激素(P)、孕激素受体(PR)的表达为评价追踪指标,对寿胎丸进行提取方法的筛选,并通过均匀设计对寿胎丸进行复方组成及配伍规律的研究,经药效验证筛选出补肾安胎的优选配比方,总结并验证了肾虚-黄体抑制大鼠流产造模的标准流程,初步建立了寿胎丸补肾安胎的药效学评价体系。
方法:
实验一:
购置组成复方的各道地药材,并进行生药鉴定。在前期研究基础结合文献研究,确定复方寿胎丸溶液的不同提取方法并制备成为寿胎丸水提液(A药液)、乙醇提取液(B药液)、醇提后药渣水提液(C药液)、醇提+醇提后药渣水提液(B+C药液)。妊娠第1日至第9日以450mg/kg/d羟基脲灌胃,第10天时予以米非司酮(RU486)4.0mg/kg建立肾虚自然流产模型。将70只SPF级SD孕鼠随机分为7个组:①正常对照组;②模型组对照组(羟基脲+米非司酮);③阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组);④寿胎丸A组(羟基脲+米非司酮+寿胎丸水提液);⑤寿胎丸B组(羟基脲+米非司酮+乙醇提液);⑥寿胎丸C组(羟基脲+米非司酮+寿胎丸乙醇提取后药渣水提液);⑦寿胎丸B+C组(羟基脲+米非司酮+寿胎丸乙醇提取液与醇提后药渣水提液的混合液)。
24小时后无菌低温条件下处死大鼠,取子宫经滤纸吸干、称重、计算胚胎数、流产率、测量胚胎直径。用电化学发光法测定血清E_2、P水平。无菌低温条件下取出同侧大鼠子宫新鲜的蜕膜组织,30分钟内采用qRT-PCR方法检测蜕膜组织PR mRNA的表达。
实验二:
通过均匀设计得到8个不同剂量配比的寿胎丸组方,将110只SPF级SD孕鼠随机分为11个组:正常对照组(简称对照组)、模型组对照组(羟基脲+米非司酮)、阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组)、8个不同配比的寿胎丸用药组。造模方法、检测方法同实验一。
分别进行多元回归分析、典型相关分析、直接最优化分析、综合加权分析,并结合均匀设计软件预报设计及临床用药经验,筛选出理论优选方。
实验三:
在实验二得出的理论优选方的基础上,将60只SPF级SD孕鼠随机分为6个组:①模型组对照组(羟基脲+米非司酮);②阳性对照组(羟基脲+米非司酮+地屈孕酮,简称阳性组);③寿胎丸临床常用量组(菟丝子:桑寄生:续断:阿胶=20:10:10:5);④寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0);⑤寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0);⑥寿胎丸优选3号方(菟丝子:桑寄生:续断:阿胶=30:21:21:5)。
造模方法与检测方法同实验一。经统计分析得出剂量配比优选方。
结果:
建立肾虚-黄体抑制大鼠流产模型的标准流程,孕鼠表现出中医肾虚证侯、脏器指数下降,流产率升高,分泌E_2、P水平降低,PRmRNA表达下调。经寿胎丸治疗后能够改善上述流产状态,抑制流产率、增加E_2、P水平,上调PRmRNA表达,来实现保护胚胎的作用。
实验一:
1寿胎丸A组、B组、C组和(B+C)组大鼠的体重、饮食量、卵巢指数、连胎子宫指数与模型组比较,差异无显著性(P＞0.05)。
2在流产率方面,寿胎丸A组、B组、C组和(B+C)组大鼠的流产率与模型组比较,差异有显著性(P＜0.05)。A组、B组、C组、B+C组大鼠的流产率与阳性对照组比较差异无显著性(P＞0.05)。A组、B组、C组、B+C组大鼠的流产率各组间比较,差异无显著性(P＞0.05)。
3在雌激素水平方面,寿胎丸A组、B组、C组和B+C组大鼠的雌二醇水平与模型组比较,差异无显著性(P＞0.05)。
4在孕激素水平方面,寿胎丸A组、B组、C组大鼠的孕激素水平与模型组比较,差异无显著性(P＞0.05)。B+C组大鼠的孕激素水平与模型组比较,差异有显著性(P＜0.05)。A组、B组、C组、B+C组大鼠的孕激素水平与阳性对照组比较,差异无显著性(P＞0.05)。
5在孕激素受体表达方面,寿胎丸A组、C组大鼠的孕激素受体的表达与模型组比较,差异无显著性(P＞0.05)。寿胎丸B组、B+C组大鼠孕激素受体的表达与模型组比较,差异有显著性(P＜0.05)。B组大鼠的孕激素受体的表达与B+C组比较,差异无显著性(P＞0.05)。
6通过等值加权综合计算各指标与模型组的相对百分率,在寿胎丸各个提取方法中,B+C组与模型组的相对百分率最高,推测B+C组防治流产的作用最强。
7综合各指标进行多元方差分析时,4个指标平衡等值加权处理后比较,差异有显著性(P＜0.05),在降低流产率方面,B+C组＞B组＞C组＞A组;在提高E_2水平方面,B+C组＞A组＞C组＞B组;在提高P水平方面,B+C组＞A组＞C组＞B组;在上调PR表达方面,B+C组＞B组＞A组＞C组。综上B+C组防治流产的作用最强。与寿胎丸各提取部位与模型组的相对百分率的推断一致。
实验二、三:
1模型组大鼠的连胎子宫指数与对照组比较,差异有显著性(P＜0.05)。阳性组、组二、组四、组五、组六组大鼠的连胎子宫指数与模型组比较,差异有显著性(P＜0.05)。
2模型组大鼠的流产率与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三、组四、组五、组六、组七和组八大鼠的流产率与模型组比较,差异有显著性(P＜0.01)。
3模型组大鼠血清中雌激素水平与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三的大鼠血清中雌激素水平与模型组比较,差异有显著性(P＜0.05)。
4模型组大鼠血清中孕激素水平与对照组比较,差异有显著性(P＜0.05)。阳性组、组一、组二、组三、组四、组六大鼠血清中孕激素水平与模型组比较,差异有显著性(P＜0.05)。
5模型组大鼠子宫蜕膜中孕激素受体表达与对照组比较,差异有显著性(P＜0.05)。组一、组二、组三、组四、组五、组六子宫蜕膜中孕激素受体与模型组比较,差异有显著性(P＜0.05)。
6寿胎丸组成药物的关系:
6.1各单味药的补肾安胎贡献度的定性分析:菟丝子＞桑寄生=续断＞阿胶。
6.2交互作用中:菟丝子与桑寄生、菟丝子与阿胶的交互作用与流产率有相关性;菟丝子与桑寄生、桑寄生与续断的交互作用与E_2有相关性;菟丝子与桑寄生、菟丝子与阿胶、桑寄生与续断、桑寄生与阿胶、续断与阿胶的交互作用与P有相关性;菟丝子与桑寄生、菟丝子与阿胶、桑寄生与续断交互作用与PR有相关性。
7将药效学指标与不同剂量配比的寿胎丸相关联,经二次回归得到的回归方程为(R~2=0.9832,P＜0.05):(?)=35.0123-0.2204*X1*X3-0.02321*X1*X4+0.2165X2X3+0.01078*X1~2得到理论优选寿胎丸方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)。
8由验证实验得出,寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)、寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0)、寿胎丸常量方(菟丝子:桑寄生:续断:阿胶=20:10:10:5)与模型组比较,差异有显著性(P＜0.05)。但组间比较,差异无统计学意义(P＞0.05)。
结论:
1罗颂平教授创立的肾虚-黄体抑制(病证结合)流产模型,成功模拟了临床上肾虚型自然流产的状态。本研究在总结前期研究的基础上,初步制定肾虚-黄体抑制(病证结合)流产模型的SOP。
2初步确立了寿胎丸的提取流程,并通过药效学实验筛选得到经醇提+醇提后水提的寿胎丸对肾虚流产大鼠模型的补肾安胎药效最优。
3验证了寿胎丸可明显降低流产率,寿胎丸具有拮抗米非司酮,促进妊娠黄体和合体滋养细胞分泌功能,提高血清E_2、P水平,通过增加孕激素受体mRNA的转录来上调PR的表达,通过改善孕鼠的肾虚状态来实现保护胚胎的作用。
4寿胎丸组成的药物关系:①各单味药的贡献度的定性分析:菟丝子＞桑寄生=续断＞阿胶;②交互作用的定性分析:菟丝子与桑寄生交互作用与各个指标均有相关性;桑寄生与续断的交互作用与E_2、P、PR有相关性;菟丝子与阿胶的交互作用与流产率、P、PR有相关性;续断与阿胶的交互作用与P有相关性。③定性研究初步证明了寿胎丸配伍关系,菟丝子与桑寄生交互作用(君臣关系)＞桑寄生与续断的交互作用(臣佐关系)＞续断与阿胶的交互作用(佐使关系);菟丝子与桑寄生交互作用(君臣关系)＞菟丝子与阿胶的交互作用(君使关系)＞续断与阿胶的交互作用(佐使关系),与原方的配伍关系基本一致。
5验证了阿胶在原方中处于使药的地位,起调和药性的作用,在本实验研究中阿胶的补肾安胎作用不显著。
6将药效学指标与不同剂量配比的寿胎丸相关联,经二次回归得到的回归方程为(R~2=0.9832,P＜0.05):(?)=35.0123-0.2204*X1*X3-0.02321*X1*X4++0.2165X2X3+0.01078*X1~2
经最优分析得出理论优选寿胎丸方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)。
7经过药效验证实验,寿胎丸优选1号方(菟丝子:桑寄生:续断:阿胶=15:21:21:0)、寿胎丸优选2号方(菟丝子:桑寄生:续断:阿胶=20:10:10:0)与寿胎丸常量方(菟丝子:桑寄生:续断:阿胶＝20:10:10:5)均具有较好的补肾安胎作用,与阳性对照药物抑制流产作用相当。寿胎丸优选2号方＞阳性对照药物＞寿胎丸优选1号方＞常量方,均可以保护胚胎、降低流产率。
8本研究初步建立了系统的寿胎丸补肾安胎作用的药效学评价体系,规范改良了造模方法、筛选了药效评价的指标,运用数学方法与计算机技术相结合研究复方组方关系和优选配比,并审慎地分析了实验结果,为寿胎丸深层次的配伍规律及药效物质基础研究奠定了基础。
Objective:
Pharmacological experiments,the effect of Shou Tai Wan(STW) on abortion animal models of corepus luteum inhibition due to renal deficiency,were performed in order to bring out the optimal extration method,the optimal proportion and the compatibility rule of STW.
Methods:
Experiment 1:
Collection of Genuine Medicinal Materials and Pharmacognostic identification of Semen Cuscutae,Herba Taxilli,Radix Dipsaci,Colla Corii asini were prepared in accordance with Chinese Pharmacopoeia.SA rats model of corepus luteum inhibition due to renal deficiency was made by intragsstric administration of hydroxycarbamide 450mg/kg/D in dioestrus.Mifepristone(RU 486) was used by intragsstric administration in 10~(th) day.SPF 70 pregnant SD rats,10 weeks old,weight 280～300g were randomly divided into 7 groups:①normal control group;②model group(Hydroxyurea + mifepristone);③positive control group(Hydroxyurea + mifepristone + dydrogeterone);④STW A(aqueous extract solution of STW);⑤STW B(ethanol-extracts of STW);⑥STW C(aqueous extract solution of guffs after alcohol extracting);⑦STW B+C(ethanol-extracts of STW + aqueous extract solution of guffs after alcohol extracting).
Generalized case of rats in every group was observered.Rats were killed after 24 hours,the following data was measured:embryos number,abortion rats sand diameter of embryos.Decidua tissue on one side was collected in 30 minutes after rats death in asepsis condition to detect expression of PR by quantitative RT-PCR.Serum estradiol(E_2),progestogen(P) were measured by chemiluminescence.
Experiment 2:
8 combinations of STW were obtained by uniform design.SPF 110 pregnant SD rats,10 weeks old,weight 280～300g were randomly divided into 11 groups:①normal control group;②model group(Hydroxyurea + mifepristone);③positive control group(Hydroxyurea + mifepristone + dydrogeterone);④8 combinations of STW by uniform design.Animal model building and detection Methods were similar to Experiment 1.
The optimal proportion of STW in theory was obtained by multiple regression analysis,canonical correlation analysis,optimum analysis,integrated weighting analysis.
Experiment 3:
SPF 60 pregnant SD rats,10 weeks old,weight280～300g were randomly divided into 6groups:①model group(Hydroxyurea + mifepristone);②positive control group(Hydroxyurea + mifepristone + dydrogeterone);③clinical routine dose of STW;④STW1(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15: 21:21:0);⑤STW 2(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20: 10:10:0);⑥STW 2(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=30: 21:21:5).Animal model building and detection Methods were similar to Experiment 1.
Results:
Experiment 1:
1.Intake of food/water,changes of pregnant rat body weight in 4~(th) and 9~(th) day,organ index in pregnant rats:compared with model group,there was no significant difference in all groups(P＞0.05).
2.Abortion rate of pregnant rat:compared with model group,there was significant difference on abortion rate between model group and other groups (P＜0.05).Compared with positive control group,there was no significant difference in STW A group,STW B group,STW C group and STW B+C group(P＞0.05).
3.The mean levels of serum E_2:compared with model group,there was no significant difference in STW A group,STW B group,STW C group and STW B+C group(P＞0.05).
4.The mean levels of serum P:compared with model group,there was no significant difference in STW A group,STW B group and STW C group(P＞0.05). The mean levels of serum P in STW B+C group was significantly different from model group(P＜0.05).Compared with positive control group,there was no significant difference in STW A group,STW B group,STW C group,STW B+C group (P＞0.05).
5.Expression of PR:compared with model group,there was no significant difference in STW A group,STW C group(P＞0.05).Expression of PR in STW B group and STW B+C group was significantly different from model group (P＜0.05).There was no significant difference between STW A group and STW C group(P＞0.05).
6.The mean relative percentages compared with model group,which was calculated by Weighted Average Method,indicated that STW B+C group was better than other groups on SA rats model model
7.Multivariate analysis of variance on 4 indexes of pharmacodynamic experiment indicated that STW B+C group＞STW B group＞STW C group＞STW A group in abortion rate of pregnant rat;STW B+C group＞STW A group＞STW C group＞STW B group in the mean levels of serum E_2;STW B+C group＞STW A group＞STW C group＞STW B group in the mean levels of serum P;STW B+C group＞STW B grou＞STW A group＞STW C group in expression of PR.It is suggested STW B+C group was better than other groups on SA rats model model.
Experiment 2:
1.Intake of food/water,changes of pregnant rat body weight in 4~(th) day:compared with model group,there was no significant difference in all groups(P＞0.05).
2.Organ index in pregnant rats:there was significant difference between control group and model group(P＜0.05).Organ index of pregnant rats in positive control group,group2,group4,group5,group6 was significantly different from model group(P＜0.05).
3.Abortion rate of pregnant rat:there was significant difference on abortion rate between control group and model group(P＜0.05).Abortion rate of pregnant rat in positive control group,group1,group2,group4, group5,group6,group7,group8 was significantly different from model group (P＜0.01).
4.The mean levels of serum E_2:there was significant difference on the levels of serum E_2 between control group and model group(P＜0.05). The mean levels of serum E_2 in positive control group,group1,group2,group3 was significantly different from model group(P＜0.05).
5.The mean levels of serum P:there was significant difference on the levels of serum P between control group and model group(P＜0.05). The mean levels of serum P in positive control group,group1,group2, group3,group4,group6 was significantly different from model group(P＜0.05).
6.Expression of PR:there was significant difference on expression of PR between control group and model group(P＜0.05).Expression of PR in group1,group2,group3,group4,group5,group6 was significantly different from model group(P＜0.05).
7.The Compatibility Rule of STW:
7.1 Qualitative Analysis of contribution degrees of single medicine in STW:
Semen Cuscutae＞Herba Taxilli=Radix Dipsaci＞Colla Corii
7.2 Qualitative Analysis of interactions of single medicine in STW:
It is suggested that abortion rate of pregnant rat is associated with interactions between Semen Cuscutae and Herba Taxilli,interactions between Semen Cuscutae and Colla Corii.The mean levels of serum E_2 is related to interactions between Semen Cuscutae and Herba Taxilli,interactions between Herba Taxilli and Radix Dipsaci.The mean levels of serum P is associated with interactions between Semen Cuscutae and Herba Taxilli, interactions between Herba Taxilli and Colla Corii,interactions between Radix Dipsaci and Colla Corii.Expression of PR is associated with 125interactions between Semen Cuscutae and Herba Taxilli,interactions between Semen Cuscutae and Colla Corii,interactions between Herba Taxilli and Radix Dipsaci.
8.Amount of each crude drug in 8 combinations of STW and the mean levels of serum E_2 and P,expression of PR results of 8 combinations of STW on abortion rat models are interrelated by quadratic regression. The equation(R~2=0.9832,P＜0.05) (?)=35.0123-0.2204*X1*X3-0.02321*X1*X4++0.2165X2X3+0.01078*X1~2 was obtained. The optimal proportion of STW are(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15:21:21:0).
9 It was concluded from authentication experiment that compared with model group,there was significant difference in STW 1 group(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=15:21:21:0),STW 2 group(Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20:10:10:0),STW 3 group (Semen Cuscutae:Herba Taxilli:adix Dipsaci:Colla Corii=20:10:10:5).
Conclusion:
1.Abortion animal models of corepus luteum inhibition due to renal deficiency,which was established by Professor Luo Song Ping,successfully analogue renal deficiency of spontaneous abortion.
引文
[1]罗颂平,张玉珍.罗元恺妇科经验集[M].上海:上海科技出版社,2005:89-90
[2]罗颂平.封藏之本,静以制动- 论罗元恺教授安胎的思路与方法[J].广州中医药大学学报.2006;9(23)5:363-365.
[3]沈自尹.从肾本质研究到证本质研究的思考与实践-中西医结合研究推动了更高层次的中医与西医互补[J].上海中医药杂志,2000;4-6.
[4]宋春风,尹桂山,吕佩源.肾阳虚证的中西医结合研究概况[J].中国中医基础医学杂志,2001;7(7):76.
[5]蔡培德,张炜.补肾中药对下丘脑GnRH、垂体FSH、LH及成骨细胞基因表达的调节作用[J].中医杂志,2002;43(3):221-223.
[6]张炜,蔡培德.补肾中药对雌性青春期大鼠垂体GnRH受体mRNA及其受体蛋白表达的影响[J].中国中西医结合杂志,2003;23(2):120-122.
[7]许丽绵,罗颂平.补肾健脾法防治自然流产的研究进展.中医药信息,2002;19(5):10-11.
[8]哈荔田.哈荔田妇科医案医话选[M].天津:天津科学出版社,1982.
[9]罗颂平,许丽绵,邓高丕.中医妇科名家医著医案导读[M].北京:人民军医出版社,2005.
[10]俞瑾.肾主生殖与生命网络研究中的启示[J].中国中西医结台杂志2000;6(6):4.
[11]徐苗厚,张振国,吕淑华.反复性早期自然流产的病因与治疗进展(上)[J].中级医刊,1997;32(7):44-46.
[12]Fatima Reis M,Aniceto P,et.Determination of environmental impacts on reproductive health and specifically on the incidence of early spontaneous abortion[J].Int J Hyg Environ Health,2007 Feb;28(2):20.
[13]Penta M,Lukic A,et.Infectious agents in tissues from spontaneous abortions in the first trimester of pregnancy.New Microbiol,2006 Oct;26(4):329-37
[14]Rao KA,Pillai JR Recurrent pregnancy loss.J Indian Med Assoc.2006 Aug;104(8):458,-460.
[15]Garrisi JG,Colls P,Ferry KM,Zheng X,Garrisi MG,Munn(?) S.Effect of infertility,maternal age,and number of previous miscarriages on the outcome of preimplantation genetic diagnosis for idiopathic recurrent pregnancy loss.Fertil Steril.2008 Aug 8.
[16]Pazarba(?)i A,Demirhan O,Turgut M,G(u|¨)zel I,Ta(?)temir D.Inheritance of a translocation between chromosomes 12 and 16 in a family with recurrent miscarriages and a newborn with Down syndrome carrying the same translocation.Genet Couns.2008:19(3):301-8.
[17]Kataoka S,Yamada T.Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy.J Clin Microbiol.2006 Jan;44(1):51-5
[18]Weselak M,Arbuckle TE,Walker MC,Krewski D.The influence of the environment and other exogenous agents on spontaneous abortion risk.J Toxicol Environ Health B Crit Rev.2008 Mar:11(3-4):221-41.
[19]罗元恺,夏桂成,李广文,等.习惯性流产的防治[J].中医杂志,1988;(4):4-6.
[20]张晋峰.夏桂成教授治疗胎动不安五法摭拾[J].中医药学刊,2001;19(2):104.
[21]归绥琪,许均.自然流产的中西医结合诊治规律初探[J].上海中医药大学学报,2001;15(2):25-27.
[22]张玉珍,刘菊芳,罗颂平,等.罗元恺教授经验方“滋肾育胎丸”临床总结(附150例疗效分析)[J].新中医,1983;(3):1.
[23]李艳玲.寿胎丸合举元煎治疗胎漏胎动不安60例[J].现代中医药,2008;28(2):34-35.
[24]肖晓玲.加味寿胎丸治疗先兆流产160例临床观察[J].黑龙江中医药,2007;36(4):31-31.
[25]宋有林.加味寿胎丸治疗先兆流产30例[J].实用中医药杂志,2006;22(7):420-421.
[26]许钧,归绥琪,等.自然流产病因分类与中医证型相关性研究——附310例临床资料分析[J].上海中医药杂志.2003:37(3):10-11.
[27]赵颖.张玉珍.助孕3号丸治疗脾虚证胎漏、胎动不安、滑胎疗效观察[J].新中医,1999;3(?)2:20-21.
[28]韩宇霞,罗颂平,黄铎香,等.自然流产患者的心理状态、个性特征与中医证候相关性的研究[J].广州中医药大学学报,2001;(18)4:311-312.
[29j曾诚,岳明明.试论先兆流产的中医证型分布规律[J].中国中医药信息杂志,2002;9(8):5.
[30]刘华,梁国珍,罗颂平.广州市部分育龄妇女早期自然流产的中医病因流行病学研究[J].中国中医急症,2004;2(13):101-102.
[31]张锡纯.《医学衷中参西录》[M].人民卫生出版社,2006
[32]郭澄,邵元福,张纯.菟丝子生物学及其应用[M].成都:成都科技大学出版社,1996;66-69.
[33]郭澄,张芝玉,苏中武,等.中药菟丝子原植物调查和本草考证[J].中国中药杂志.1990;5(3):138-144.
[34]徐国均.生药学[M].北京:人民卫生出版社,1989:530
[35]阿依木古丽,蔡勇.中药菟丝子的生物学研究[J].西北民族人学学报(自然科学版)2006;27(3)76-78.
[36]陈亚琼,黄艳红,辛晓燕,等.菟丝子复方对大鼠性腺轴形态和功能的影响[J].第四军医 大学学报,2001;21(3);45.
[37]曾诚,罗颂平,宓穗卿,等.菟丝子活性成分槲皮素含量测定中HPCL方法的建立[J].中国中医药信息杂志.2004;11(8):701-703.
[38]王建红,王敏璋,欧阳栋,等.菟丝子黄酮对心理应激雌性大鼠下丘脑β-EP与腺体FSH、1H的影响[J].中药材,2002;25(12):886.
[39]马红霞,尤昭玲.菟丝子总黄酮对大鼠流产模型血清P、PR、Th1/Th2细胞因子表达的影响[J].中药材,2008;31(8):1201-1204.
[40]马红霞,尤昭玲.菟丝子总黄酮对大鼠流产模型妊娠结局及胎盘、蜕膜形态学的影响[J].中药材.2008;31(7):1044-1046.
[41]吴克让,等.几种中药对家兔离体子宫活动的影响及其配伍作用的实验观察[J].浙江中医学院学报,1983;7(增刊):2.
[42]龚小健,等.川续断对离体子宫的作用[J]。中国药科大学学报,1995,26(2):115.
[43]龚晓健,等.川续断总生物碱对妊娠大鼠子宫的抗致痉及抗流产作用[J].中国药科大学学报,1998;29(6):459.
[44]龚小健,等.川续断DA303对大鼠子宫的作用[J].中国药科大学学报,1996;27(1):48.
[45]李小球.补肾健脾中药对妊娠大鼠孕激素及其受体的影响[J]广州中医药大学学报.1998;15(3):208-210.
[46]张铭.助孕3号方对脾虚黄体抑制动物流产模型的作用[J]广州中医药大学学报.2000;17(1):64-66.
[47]宁艳,等.补肾健脾中药复方对肾虚黄体抑制妊娠大鼠流产模型的实验研究[J]
[48]刘昱磊,罗颂平,梁国珍.助孕3号方及拆方防治肾虚黄体抑制动物流产模型的实验研究[J].生殖与免疫,2003;1(23):17-20.
[49]丘明明.先兆流产证侯分布规律与补肾组方PR表达的调控.广州中医药大学学位论文,2003
[50]陈伟仁.助孕3号方对先兆流产模型大鼠子宫兴奋性的影响.广州中医药大学学位论文,2005
[51]赵新广,等.寿胎丸对KM小鼠PCE/NCE比值及MNPCE率的影响[J].湖南中医药大学学报,2008;28(3):8-9,34.
[52]刘丹卓,尤昭玲,等.寿胎丸对TA97、TA98、TAl00、TA102菌株基因回变菌落的影响[J].湖南中医药大学学报,2008;28(3):5-7.
[53]赵颖.拟除虫菊酯生殖和神经毒性及补肾健脾中药干预作用的研究.广州中医药大学学位论文,2005.
[54]濮家伉.寿胎丸提取物对大鼠离体子宫平滑肌收缩作用的影响[J].南京铁道医学院学报,1995;14(4):225-227.
[55]丁立等.寿胎丸的药效学和毒理学研究[J].中药药理与临床,1997;13(5):5-8.
[56]邓高丕,陶莉莉,等.寿胎丸加味方合煎与单煎混合浓缩颗粒的临床等效性研究[J].中药材2001;24(9):694-695
[57]董燕.助孕3号方等补肾中药安胎后子代的体格和智力发育情况.广州中医药大学学位论文,2004
[58]Parmaceutical Iudustry Profile 2004,Parmaceutical Research and Manufacturers of America,Washington DC,2004.
[59]Booth B.and Zemmel R.Nat.Rev.Drug.Disc.2004,3,451-456.
[60]梁琼麟,罗国安.中药复方新药创制及技术支撑体系[J].世界科学技术—中医药现代化.2008;10(13):1-6.
[61]夏征农.辞源.上海:辞书出版社.1999.
[62]韩笑,胡一冰,邱德文.中药复方配伍规律研究[J].中国中医基础医学杂志,2000;6(8):59-64.
[63]余林中,罗佳波,谭晓梅.方剂配伍规律研究应以物质基础为核心[J].中国中医基础医学杂志,1999:10(5):18.
[64]宋小莉,高艳青,牛欣,司银楚.复方配伍实验设计方法评述[J].中西医结合学报,2003;1(3):177-179.
[65]商洪才,张伯礼,王永炎,等.一种适用于中药小复方配比优选设计方法的建立[J].中国实验方剂学杂志,2003;9(3):1-3.
[66]张伯礼.高秀梅.王永炎.复方丹参方的药效物质及作用机理研究[J].世界科学技术—中医药现代化,2003;5(5):14-17.
[67]商洪才,张伯礼,高秀梅,等.丹参/三七不同配比药效学比较研究—对急性实验性心肌缺血犬心肌生化标志物的影响[J].天津中医.2002;19(2):43-45.
[68]余林中,罗佳波,谭晓梅.方剂组成原理基础研究思路[J].中药药理与临床.2000;16(3):43-45.
[69]宋宗华,戴舒佳,黎辉琴.苓桂术甘汤配伍机制研究[J].中国中药杂志,2002;27(10):760-762
[70]田峰,王新瑞,朴晋华,等.多囊平煎剂组方对大鼠高睾酮血症影响的正交设计[J].中国药物与临床,2002;2(5):289-292.
[71]田维毅,等.小儿泻停方的抗菌效应及其优化组方研究[J].四川中医,2006;24(8):97-98.
[72]邢雅玲,等.均匀设计法筛选中药醒神方的药物用量[J].中国实验方剂学杂志,2006:12(1):25-27.
[73]叶勇等.均匀设计对茶叶咖啡碱戒毒制剂中药组方的配伍优化研究[J].云南中医学院学报,2006;29(1):17-19.
[74]吴敏毓,米娜,孙卫民.补中益气汤拆方组分对脾虚小鼠免疫调节作用[J].中国临床药理学与治疗学杂志,1997;2(2):144-145.
[75]王国庆,李宇航,赵琰,等.半夏泻心汤配伍规律的拆方研究(Ⅲ)—对正常大鼠十二指肠肌电的影响[J].北京中医药大学学报,2001;24(6):19-21.
[76]刘保林,温文清,朱丹妮,等.六味地黄汤及其拆方对小鼠血糖和肝糖元的影响[J].中国中药杂志,1991;16(7):437-438.
[77]袁栎,吴敏毓,孙瑞元.复方六一汤及其拆方组方对血虚小鼠细胞免疫功能的影响[J].中国临床药理学与治疗学,2002;7(1):35-36.
[78]米娜,吴敏毓,孙卫民.拆方研究补中益气汤中黄芩、甘草及全方的免疫调节作用[J].皖南医学院学报,2002;21(1):13.
[79]吕景山.施今墨对药临床经验集[M].太原山西人民出版社,1982:56
[80]Zhang Mei,Su Xiaolin,Yu Tion Changes of the Contents of the Active Components in 5 Chinese Medicinals after Combined with Aconite[J].World Science and Technology-Modernization of Traditional Chinese Medicine and Materia Medica.2006:8(3):27-29.
[81]姚新生,胡柯.中药复方的现代化研究[J].化学进展,2006;11:192-196.
[1]叶敏,阎玉凝,乔梁,等.中药菟丝子的化学成分研究[J].中国中药杂志,2002;27(2):115-116.
[2]王刚,杨松松,曹阳.大孔吸附树脂法富集菟丝子总黄酮的实验研究[J].中华中医药学刊,200725(9):1964-1965.
[3]陈乐生.桑寄生药理研究[J].陕西中医,2000;21(11):520-521.
[4]龚祝南,王燕飞,梁侨丽,王峥涛,徐珞珊,徐国钧.中国桑寄生科植物化学成分分类学研究[J].广西植物,2004;24(6):493-496.
[5]魏峰,等.续断类的研究[M].常用中药材品种整理和质量研究,第6册[M].北京:北京医科大学出版社.2003;105.
[6]陈振江,张桂枝,刘静芬,等.阿胶及其伪品的IFE研究[J].中成药,1998;20(12):31.
[7]徐康森,张林可.阿胶真伪鉴别和内在质量的研究Ⅱ.阿胶与其它胶的等电点研究[J].药物分析杂志,1989;9(4):210.
[8]陈林林,吴春,蒋意桥.菟丝子总黄酮提取工艺的研究[J].哈尔滨商业大学学报(自然科学版),2004;20(6):644-647.
[9]苏燕评,刘育梅,陈炳华,刘剑秋.红花桑寄生枝叶总黄酮提取工艺.亚热带植物科学.2002:31(2):21-24.
[10]吕琳,宇明,徐东铭.桑寄生中槲皮素、槲皮苷的鉴定与含量测定[J].中成药,2004;26(12):1046-1048.
[11]董玉琼,何晓红,钟国跃,李隆云,罗维早.正交法优选川续断的提取工艺[J].国中药杂志.2007;32(11):107-109.
[12]汪建平,张长弓,刘先超,王瑞昙.炮制对续断理化性质的影响研究[J].中药材.2006;29(9):895-897.
[13]赵丽,张长弓,钟巧妮,雷玉霞,程明,王仲.大孔吸附树脂分离纯化五鹤续断总皂苷的工艺研究[J].医药导报.2007:26(6):649-651.
[14]Zhang SJ,Ma LY,Huang QH,el at.Gain-of-function mutation of GA-TA-2 in acute myeloid transformation of chronic myeloid leukemia,PROCEEDING OF THE NATIONAL ACADEMYOF SCIENCES OF THE UNITED STATES OF AMERICA,2008"105(6):2076-2081.
[2]罗颂平.封藏之本,静以制动- 论罗元恺教授安胎的思路与方法[J].广州中医药大学学报.2006;9(23)5:363-365.
[3]沈自尹.从肾本质研究到证本质研究的思考与实践-中西医结合研究推动了更高层次的中医与西医互补[J].上海中医药杂志,2000;4-6.
[4]宋春风,尹桂山,吕佩源.肾阳虚证的中西医结合研究概况[J].中国中医基础医学杂志,2001;7(7):76.
[5]蔡培德,张炜.补肾中药对下丘脑GnRH、垂体FSH、LH及成骨细胞基因表达的调节作用[J].中医杂志,2002;43(3):221-223.
[6]张炜,蔡培德.补肾中药对雌性青春期大鼠垂体GnRH受体mRNA及其受体蛋白表达的影响[J].中国中西医结合杂志,2003;23(2):120-122.
[7]许丽绵,罗颂平.补肾健脾法防治自然流产的研究进展.中医药信息,2002;19(5):10-11.
[8]哈荔田.哈荔田妇科医案医话选[M].天津:天津科学出版社,1982.
[9]罗颂平,许丽绵,邓高丕.中医妇科名家医著医案导读[M].北京:人民军医出版社,2005.
[10]俞瑾.肾主生殖与生命网络研究中的启示[J].中国中西医结台杂志2000;6(6):4.
[11]徐苗厚,张振国,吕淑华.反复性早期自然流产的病因与治疗进展(上)[J].中级医刊,1997;32(7):44-46.
[12]Fatima Reis M,Aniceto P,et.Determination of environmental impacts on reproductive health and specifically on the incidence of early spontaneous abortion[J].Int J Hyg Environ Health,2007 Feb;28(2):20.
[13]Penta M,Lukic A,et.Infectious agents in tissues from spontaneous abortions in the first trimester of pregnancy.New Microbiol,2006 Oct;26(4):329-37
[14]Rao KA,Pillai JR Recurrent pregnancy loss.J Indian Med Assoc.2006 Aug;104(8):458,-460.
[15]Garrisi JG,Colls P,Ferry KM,Zheng X,Garrisi MG,Munn(?) S.Effect of infertility,maternal age,and number of previous miscarriages on the outcome of preimplantation genetic diagnosis for idiopathic recurrent pregnancy loss.Fertil Steril.2008 Aug 8.
[16]Pazarba(?)i A,Demirhan O,Turgut M,G(u|¨)zel I,Ta(?)temir D.Inheritance of a translocation between chromosomes 12 and 16 in a family with recurrent miscarriages and a newborn with Down syndrome carrying the same translocation.Genet Couns.2008:19(3):301-8.
[17]Kataoka S,Yamada T.Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy.J Clin Microbiol.2006 Jan;44(1):51-5
[18]Weselak M,Arbuckle TE,Walker MC,Krewski D.The influence of the environment and other exogenous agents on spontaneous abortion risk.J Toxicol Environ Health B Crit Rev.2008 Mar:11(3-4):221-41.
[19]罗元恺,夏桂成,李广文,等.习惯性流产的防治[J].中医杂志,1988;(4):4-6.
[20]张晋峰.夏桂成教授治疗胎动不安五法摭拾[J].中医药学刊,2001;19(2):104.
[21]归绥琪,许均.自然流产的中西医结合诊治规律初探[J].上海中医药大学学报,2001;15(2):25-27.
[22]张玉珍,刘菊芳,罗颂平,等.罗元恺教授经验方“滋肾育胎丸”临床总结(附150例疗效分析)[J].新中医,1983;(3):1.
[23]李艳玲.寿胎丸合举元煎治疗胎漏胎动不安60例[J].现代中医药,2008;28(2):34-35.
[24]肖晓玲.加味寿胎丸治疗先兆流产160例临床观察[J].黑龙江中医药,2007;36(4):31-31.
[25]宋有林.加味寿胎丸治疗先兆流产30例[J].实用中医药杂志,2006;22(7):420-421.
[26]许钧,归绥琪,等.自然流产病因分类与中医证型相关性研究——附310例临床资料分析[J].上海中医药杂志.2003:37(3):10-11.
[27]赵颖.张玉珍.助孕3号丸治疗脾虚证胎漏、胎动不安、滑胎疗效观察[J].新中医,1999;3(?)2:20-21.
[28]韩宇霞,罗颂平,黄铎香,等.自然流产患者的心理状态、个性特征与中医证候相关性的研究[J].广州中医药大学学报,2001;(18)4:311-312.
[29j曾诚,岳明明.试论先兆流产的中医证型分布规律[J].中国中医药信息杂志,2002;9(8):5.
[30]刘华,梁国珍,罗颂平.广州市部分育龄妇女早期自然流产的中医病因流行病学研究[J].中国中医急症,2004;2(13):101-102.
[31]张锡纯.《医学衷中参西录》[M].人民卫生出版社,2006
[32]郭澄,邵元福,张纯.菟丝子生物学及其应用[M].成都:成都科技大学出版社,1996;66-69.
[33]郭澄,张芝玉,苏中武,等.中药菟丝子原植物调查和本草考证[J].中国中药杂志.1990;5(3):138-144.
[34]徐国均.生药学[M].北京:人民卫生出版社,1989:530
[35]阿依木古丽,蔡勇.中药菟丝子的生物学研究[J].西北民族人学学报(自然科学版)2006;27(3)76-78.
[36]陈亚琼,黄艳红,辛晓燕,等.菟丝子复方对大鼠性腺轴形态和功能的影响[J].第四军医 大学学报,2001;21(3);45.
[37]曾诚,罗颂平,宓穗卿,等.菟丝子活性成分槲皮素含量测定中HPCL方法的建立[J].中国中医药信息杂志.2004;11(8):701-703.
[38]王建红,王敏璋,欧阳栋,等.菟丝子黄酮对心理应激雌性大鼠下丘脑β-EP与腺体FSH、1H的影响[J].中药材,2002;25(12):886.
[39]马红霞,尤昭玲.菟丝子总黄酮对大鼠流产模型血清P、PR、Th1/Th2细胞因子表达的影响[J].中药材,2008;31(8):1201-1204.
[40]马红霞,尤昭玲.菟丝子总黄酮对大鼠流产模型妊娠结局及胎盘、蜕膜形态学的影响[J].中药材.2008;31(7):1044-1046.
[41]吴克让,等.几种中药对家兔离体子宫活动的影响及其配伍作用的实验观察[J].浙江中医学院学报,1983;7(增刊):2.
[42]龚小健,等.川续断对离体子宫的作用[J]。中国药科大学学报,1995,26(2):115.
[43]龚晓健,等.川续断总生物碱对妊娠大鼠子宫的抗致痉及抗流产作用[J].中国药科大学学报,1998;29(6):459.
[44]龚小健,等.川续断DA303对大鼠子宫的作用[J].中国药科大学学报,1996;27(1):48.
[45]李小球.补肾健脾中药对妊娠大鼠孕激素及其受体的影响[J]广州中医药大学学报.1998;15(3):208-210.
[46]张铭.助孕3号方对脾虚黄体抑制动物流产模型的作用[J]广州中医药大学学报.2000;17(1):64-66.
[47]宁艳,等.补肾健脾中药复方对肾虚黄体抑制妊娠大鼠流产模型的实验研究[J]
[48]刘昱磊,罗颂平,梁国珍.助孕3号方及拆方防治肾虚黄体抑制动物流产模型的实验研究[J].生殖与免疫,2003;1(23):17-20.
[49]丘明明.先兆流产证侯分布规律与补肾组方PR表达的调控.广州中医药大学学位论文,2003
[50]陈伟仁.助孕3号方对先兆流产模型大鼠子宫兴奋性的影响.广州中医药大学学位论文,2005
[51]赵新广,等.寿胎丸对KM小鼠PCE/NCE比值及MNPCE率的影响[J].湖南中医药大学学报,2008;28(3):8-9,34.
[52]刘丹卓,尤昭玲,等.寿胎丸对TA97、TA98、TAl00、TA102菌株基因回变菌落的影响[J].湖南中医药大学学报,2008;28(3):5-7.
[53]赵颖.拟除虫菊酯生殖和神经毒性及补肾健脾中药干预作用的研究.广州中医药大学学位论文,2005.
[54]濮家伉.寿胎丸提取物对大鼠离体子宫平滑肌收缩作用的影响[J].南京铁道医学院学报,1995;14(4):225-227.
[55]丁立等.寿胎丸的药效学和毒理学研究[J].中药药理与临床,1997;13(5):5-8.
[56]邓高丕,陶莉莉,等.寿胎丸加味方合煎与单煎混合浓缩颗粒的临床等效性研究[J].中药材2001;24(9):694-695
[57]董燕.助孕3号方等补肾中药安胎后子代的体格和智力发育情况.广州中医药大学学位论文,2004
[58]Parmaceutical Iudustry Profile 2004,Parmaceutical Research and Manufacturers of America,Washington DC,2004.
[59]Booth B.and Zemmel R.Nat.Rev.Drug.Disc.2004,3,451-456.
[60]梁琼麟,罗国安.中药复方新药创制及技术支撑体系[J].世界科学技术—中医药现代化.2008;10(13):1-6.
[61]夏征农.辞源.上海:辞书出版社.1999.
[62]韩笑,胡一冰,邱德文.中药复方配伍规律研究[J].中国中医基础医学杂志,2000;6(8):59-64.
[63]余林中,罗佳波,谭晓梅.方剂配伍规律研究应以物质基础为核心[J].中国中医基础医学杂志,1999:10(5):18.
[64]宋小莉,高艳青,牛欣,司银楚.复方配伍实验设计方法评述[J].中西医结合学报,2003;1(3):177-179.
[65]商洪才,张伯礼,王永炎,等.一种适用于中药小复方配比优选设计方法的建立[J].中国实验方剂学杂志,2003;9(3):1-3.
[66]张伯礼.高秀梅.王永炎.复方丹参方的药效物质及作用机理研究[J].世界科学技术—中医药现代化,2003;5(5):14-17.
[67]商洪才,张伯礼,高秀梅,等.丹参/三七不同配比药效学比较研究—对急性实验性心肌缺血犬心肌生化标志物的影响[J].天津中医.2002;19(2):43-45.
[68]余林中,罗佳波,谭晓梅.方剂组成原理基础研究思路[J].中药药理与临床.2000;16(3):43-45.
[69]宋宗华,戴舒佳,黎辉琴.苓桂术甘汤配伍机制研究[J].中国中药杂志,2002;27(10):760-762
[70]田峰,王新瑞,朴晋华,等.多囊平煎剂组方对大鼠高睾酮血症影响的正交设计[J].中国药物与临床,2002;2(5):289-292.
[71]田维毅,等.小儿泻停方的抗菌效应及其优化组方研究[J].四川中医,2006;24(8):97-98.
[72]邢雅玲,等.均匀设计法筛选中药醒神方的药物用量[J].中国实验方剂学杂志,2006:12(1):25-27.
[73]叶勇等.均匀设计对茶叶咖啡碱戒毒制剂中药组方的配伍优化研究[J].云南中医学院学报,2006;29(1):17-19.
[74]吴敏毓,米娜,孙卫民.补中益气汤拆方组分对脾虚小鼠免疫调节作用[J].中国临床药理学与治疗学杂志,1997;2(2):144-145.
[75]王国庆,李宇航,赵琰,等.半夏泻心汤配伍规律的拆方研究(Ⅲ)—对正常大鼠十二指肠肌电的影响[J].北京中医药大学学报,2001;24(6):19-21.
[76]刘保林,温文清,朱丹妮,等.六味地黄汤及其拆方对小鼠血糖和肝糖元的影响[J].中国中药杂志,1991;16(7):437-438.
[77]袁栎,吴敏毓,孙瑞元.复方六一汤及其拆方组方对血虚小鼠细胞免疫功能的影响[J].中国临床药理学与治疗学,2002;7(1):35-36.
[78]米娜,吴敏毓,孙卫民.拆方研究补中益气汤中黄芩、甘草及全方的免疫调节作用[J].皖南医学院学报,2002;21(1):13.
[79]吕景山.施今墨对药临床经验集[M].太原山西人民出版社,1982:56
[80]Zhang Mei,Su Xiaolin,Yu Tion Changes of the Contents of the Active Components in 5 Chinese Medicinals after Combined with Aconite[J].World Science and Technology-Modernization of Traditional Chinese Medicine and Materia Medica.2006:8(3):27-29.
[81]姚新生,胡柯.中药复方的现代化研究[J].化学进展,2006;11:192-196.
[1]叶敏,阎玉凝,乔梁,等.中药菟丝子的化学成分研究[J].中国中药杂志,2002;27(2):115-116.
[2]王刚,杨松松,曹阳.大孔吸附树脂法富集菟丝子总黄酮的实验研究[J].中华中医药学刊,200725(9):1964-1965.
[3]陈乐生.桑寄生药理研究[J].陕西中医,2000;21(11):520-521.
[4]龚祝南,王燕飞,梁侨丽,王峥涛,徐珞珊,徐国钧.中国桑寄生科植物化学成分分类学研究[J].广西植物,2004;24(6):493-496.
[5]魏峰,等.续断类的研究[M].常用中药材品种整理和质量研究,第6册[M].北京:北京医科大学出版社.2003;105.
[6]陈振江,张桂枝,刘静芬,等.阿胶及其伪品的IFE研究[J].中成药,1998;20(12):31.
[7]徐康森,张林可.阿胶真伪鉴别和内在质量的研究Ⅱ.阿胶与其它胶的等电点研究[J].药物分析杂志,1989;9(4):210.
[8]陈林林,吴春,蒋意桥.菟丝子总黄酮提取工艺的研究[J].哈尔滨商业大学学报(自然科学版),2004;20(6):644-647.
[9]苏燕评,刘育梅,陈炳华,刘剑秋.红花桑寄生枝叶总黄酮提取工艺.亚热带植物科学.2002:31(2):21-24.
[10]吕琳,宇明,徐东铭.桑寄生中槲皮素、槲皮苷的鉴定与含量测定[J].中成药,2004;26(12):1046-1048.
[11]董玉琼,何晓红,钟国跃,李隆云,罗维早.正交法优选川续断的提取工艺[J].国中药杂志.2007;32(11):107-109.
[12]汪建平,张长弓,刘先超,王瑞昙.炮制对续断理化性质的影响研究[J].中药材.2006;29(9):895-897.
[13]赵丽,张长弓,钟巧妮,雷玉霞,程明,王仲.大孔吸附树脂分离纯化五鹤续断总皂苷的工艺研究[J].医药导报.2007:26(6):649-651.
[14]Zhang SJ,Ma LY,Huang QH,el at.Gain-of-function mutation of GA-TA-2 in acute myeloid transformation of chronic myeloid leukemia,PROCEEDING OF THE NATIONAL ACADEMYOF SCIENCES OF THE UNITED STATES OF AMERICA,2008"105(6):2076-2081.